申请人:Merck & Co., Inc.
公开号:US05457107A1
公开(公告)日:1995-10-10
This invention is concerned with a novel polymorphic form of the compound 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo )methyl)-3-(S)-phenyl-morpholine which is a tachykinin receptor antagonist useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic form has advantages over the other known forms of 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo )methyl)-3-(S)-phenyl-morpholine in terms of thermodynamic stability and suitability for inclusion in pharmaceutical formulations.
本发明涉及一种新的多形态化合物,即2-(S)-(3,5-双三氟甲基苯氧基)-4-(3-(5-氧代-1H,4H-1,2,4-三唑)甲基)-3-(S)-苯基-吗啡啡啶,该化合物是一种抗速激肽受体拮抗剂,可用于治疗炎症性疾病、疼痛或偏头痛、哮喘和呕吐。该瞬时多形态具有比2-(S)-(3,5-双三氟甲基苯氧基)-4-(3-(5-氧代-1H,4H-1,2,4-三唑)甲基)-3-(S)-苯基-吗啡啡啶的其他已知形式更好的热力学稳定性和适合纳入制药配方的优点。